TH9507: A Growth Hormone Releasing Factor Analog for HIV-Associated Lipodystrophy
Background
HIV-associated lipodystrophy is a common complication in patients receiving combination antiretroviral therapy (ART), characterized by excess visceral fat accumulation alongside a loss of subcutaneous fat, often leading to dyslipidemia and insulin resistance. Previous research has shown that TH9507, a growth hormone releasing factor (GRF) analog, can reduce visceral and trunk fat. This Phase 3 study was designed to further assess the efficacy and safety of 2 mg TH9507 in a larger population of HIV patients with excess abdominal fat accumulation, building on promising earlier results.
Results
The abstract for this Phase 3 study primarily provides context by referencing findings from a previous randomized, placebo-controlled trial that justified the current investigation. In that prior study, daily administration of 2 mg TH9507 for 12 weeks resulted in significant decreases in visceral adipose tissue (VAT) (fat surrounding internal organs) and trunk fat. These reductions in visceral adipose tissue (VAT) and trunk fat were observed without significant changes in limb fat or subcutaneous adipose tissue (SAT), indicating a targeted effect on problematic fat accumulation. The current Phase 3 study was initiated to further confirm these promising efficacy and safety profiles in a larger, more robust patient cohort, but its specific results are not presented in this abstract.
Why It Matters
The potential of TH9507 to selectively reduce visceral adipose tissue (VAT) in HIV patients with lipodystrophy is highly significant, as this fat accumulation is strongly linked to serious metabolic complications like dyslipidemia and insulin resistance. A successful Phase 3 trial confirming these targeted fat reductions could offer a crucial therapeutic option for a challenging aspect of HIV management, potentially improving patient quality of life and reducing long-term health risks associated with metabolic dysfunction. Confirmation of these benefits in a larger cohort could pave the way for clinical approval and widespread use, addressing an unmet medical need.